製品番号: HY-15310

イベルメクチン

(別名: Ivermectin; MK-933)

48 Cited Publications

カスタマーレビュー

Based on 48 publication(s) in Google Scholar

Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.28%
CAS 番号: 70288-86-7
分子式: C₄₈H₇₄O₁₄
分子量:875.09

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Ivermectin 構造式

CAS 番号: 70288-86-7

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 臨床実験
化学情報
Publications (48)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import^[1]^[2]^[3]^[4]. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19^[5].

IC₅₀ & Target^[1]

HIV-1

DNA Polymerase

HSV-1

BoHV-1

SARS-CoV-2

HIV アイソフォーム固有の製品をすべて表示 :

Antibiotic アイソフォーム固有の製品をすべて表示 :

Parasite アイソフォーム固有の製品をすべて表示 :

HSV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	10.42 μM Compound: 2a; Fig 11, Cpd 2, MK933	Antimalarial activity against Plasmodium cynomolgi infected in rhesus macaque hepatocytes assessed as inhibition of liver-stage schizonts by Giemsa staining based microscopic analysis Antimalarial activity against Plasmodium cynomolgi infected in rhesus macaque hepatocytes assessed as inhibition of liver-stage schizonts by Giemsa staining based microscopic analysis	[PMID: 34242031]
Huh-7	IC₅₀	2.1 μM Compound: 2a; Fig 11, Cpd 2, MK933	Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay Antimalarial activity against liver stage Plasmodium berghei infected in human Huh-7 cells assessed as inhibition by bioluminescence assay	[PMID: 34242031]
LLC-PK1	IC₅₀	0.1 μM Compound: Ivermectin	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	0.5 μM Compound: Ivermectin	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
Macrophage	IC₅₀	72.4 μM Compound: 1, IVM	Cytotoxicity against mouse peritoneal macrophages assessed as LDH release after 48 hrs Cytotoxicity against mouse peritoneal macrophages assessed as LDH release after 48 hrs	[PMID: 19114308]
Macrophage	CC₅₀	427.5 μM Compound: IVM	Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse macrophage assessed as cell viability measured after 48 hrs by MTT assay	[PMID: 37793327]
Vero	CC₅₀	52.84 μg/mL Compound: Ivermectin	Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin dye-based fluorimetric analysis Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin dye-based fluorimetric analysis	[PMID: 22348826]
Vero	CC₅₀	230 μM Compound: Ivermectin	Cytotoxicity against African green monkey Vero C1008 cells assessed as cell death by three-fold serial dilution method Cytotoxicity against African green monkey Vero C1008 cells assessed as cell death by three-fold serial dilution method	[PMID: 24863844]
Vero	CC₅₀	53.15 μM Compound: Ivermectin	Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 25768703]
Vero	CC₅₀	53.15 μM Compound: Ivermectin	Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorometric analysis Cytotoxicity against African green monkey Vero cells after 72 hrs by resazurin dye-based fluorometric analysis	[PMID: 26383126]

体外実験

In the submicromolar range (EC₅₀=250 nM) the action of Ivermectin (MK-933) is rapid and reversible, resulting in increased amplitude and slowed deactivation of P2X₄ channel currents evoked by ATP^[1].
Ivermectin (MK-933) markedly increases the potency of ATP and that of the normally low-potency agonist a,b-methylene-ATP in a use- and voltage-independent manner without changing the ion selectivity of P2X₄ channels^[1].
Ivermectin (MK-933) activates glutamate-gated chloride channels in the nerves and muscles of the parasite, leading to membrane hyperpolarization and muscle paralysis^[2].
Ivermectin (MK-933) strongly inhibits the binding of Impα/β1 to NS5 (IC₅₀=17 μM), but not of Impβ1 alone to NS5^[3].
Ivermectin (MK-933) has potent antiviral activity towards both HIV-1 and dengue virus, both of which are strongly reliant on importin α/β nuclear import, with respect to the HIV-1 integrase and NS5 (non-structural protein 5) polymerase proteins respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 70288-86-7
性状 Solid
分子量 875.09
分子式 C₄₈H₇₄O₁₄
Color White to off-white
SMILES

CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@H](/C(C)=C/C[C@@H]3C[C@H]4C[C@@]5(O[C@]([H])(C(C)C)[C@@H](C)CC5)O3)[C@@H](C)/C=C/C=C6CO[C@@]7([H])[C@]\6(O)[C@H](C(O4)=O)C=C(C)[C@H]7O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O.CO[C@H]8C[C@H](O[C@H]9[C@H](C)O[C@@H](O[C@H](/C(C)=C/C[C@@H]%10C[C@H]%11C[C@@]%12(O[C@]([H])([C@@H](C)CC)[C@@H](C)CC%12)O%10)[C@@H](C)/C=C/C=C%13CO[C@@]%14([H])[C@]\%13(O)[C@H](C(O%11)=O)C=C(C)[C@H]%14O)C[C@@H]9OC)O[C@@H](C)[C@@H]8O
別名

Ivermectin; MK-933
Structure Classification
- Antibiotics
- Macrolide Antibiotics
Initial Source
- Microorganisms
Streptomyces avermitilis
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (48)

All In Vivo Efficacy StudyWBFlow CytometryCell Autophagy Assay

Sort by:

Journal Impact Factor

Cell

A host organelle integrates stolen chloroplasts for animal photosynthesis. [Abstract]

2025 Sep 18;188(19):5266-5277.e13. PMID: 40570835
Cell Mol Immunol

ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia. [Abstract]

2022 Aug;19(8):898-912. PMID: 35637282

Ivermectin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):898-912. [Abstract]

Ivermectin (1-3 mg/kg; i.p.). Platelet counts in WT (upper panel) and Adap^−/− mice (lower panel) treated with Ivermectin or saline over a time course of 5 days.

Ivermectin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Aug;19(8):898-912. [Abstract]

Ivermectin (1-3 mg/kg; i.p.). FcγR expressions on resting and IFN-γ-treated splenic macrophages in WT and Adap^−/− mice treated with ivermectin for 5 days from.
Autophagy

Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model. [Abstract]

2022 Mar;18(3):559-575. PMID: 34092198

Ivermectin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Mar;18(3):559-575. [Abstract]

Ivermectin (IVE; 10 μM; 24 h). Hs-SNCA, p-SNCA, LC3-II and SQSTM1/p62 levels were elevated by western blotting.

Ivermectin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 Mar;18(3):559-575. [Abstract]

Ivermectin (IVE; 10 μM; 24 h). Autophagy flux was evaluated by counting autophagosome (RFP-GFP double positive puncta) and autolysosomes (RFP-single positive puncta) in mRFP-GFP-LC3 primary neurons.
Adv Sci (Weinh)

SRSF5-Mediated Alternative Splicing of M Gene is Essential for Influenza A Virus Replication: A Host-Directed Target Against Influenza Virus. [Abstract]

2022 Dec;9(34):e2203088. PMID: 36257906
Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Sci Adv

Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. [Abstract]

2025 Aug 15;11(33):eadx6587. PMID: 40815641

Ivermectin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Aug 15;11(33):eadx6587. [Abstract]

Ivermectin (IVM; 12.5 mg/kg; ip). Tumor growth of B16 in C57BL/6 mice treated with IVM, α-PD-1, or both.
Redox Biol

SMURF2 attenuates NRF2-driven tumor progression by acting as a nuclear brake on NRF2 during cellular stress. [Abstract]

2026 May:92:104102. PMID: 41926909
Cancer Lett

Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma. [Abstract]

2023 Jul 1:565:216218. PMID: 37149018
Biomater Res

Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma. [Abstract]

2025 Nov 6:29:0278. PMID: 41209313
EMBO J

TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis. [Abstract]

2022 Apr 22:e110324. PMID: 35451091
Apoptosis

The role of KPNA3 in multiple myeloma: implications for targeting nuclear import. [Abstract]

2026 Mar 11;31(3):98. PMID: 41813919
Biomed Pharmacother

Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma. [Abstract]

2024 Jun 20:177:116991. PMID: 38906021
Biomed Pharmacother

Ivermectin contributes to attenuating the severity of acute lung injury in mice. [Abstract]

2022 Nov:155:113706. PMID: 36116250
Cell Death Discov

Mutant p53 upregulates HDAC6 to resist ER stress and facilitates Ku70 deacetylation, which prevents its degradation and mitigates DNA damage in colon cancer cells. [Abstract]

2025 Apr 10;11(1):162. PMID: 40210861
Clin Transl Med

P2X4 receptor modulates gut inflammation and favours microbial homeostasis in colitis. [Abstract]

2023 Apr;13(4):e1227. PMID: 37085966
Antioxidants (Basel)

Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species. [Abstract]

2024 May 29;13(6):667. PMID: 38929106
Commun Med (Lond)

AI-enabled drug prediction and gene network analysis reveal therapeutic use of vorinostat for Rett Syndrome in preclinical models. [Abstract]

2025 Jul 1;5(1):249. PMID: 40595330
JCI Insight

HSP70 is a chaperone for IL-33 activity in chronic airway disease. [Abstract]

2025 Jun 24;10(15):e193640. PMID: 40553562
Inflammation

Ivermectin Protects Against Experimental Autoimmune Encephalomyelitis in Mice by Modulating the Th17/Treg Balance Involved in the IL-2/STAT5 Pathway. [Abstract]

2023 Oct;46(5):1626-1638. PMID: 37227550
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
Pharmaceuticals (Basel)

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis. [Abstract]

2024 Apr 29;17(5):569. PMID: 38794139
Front Pharmacol

Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth. [Abstract]

2021 Aug 13;12:717529. PMID: 34483925
Int Immunopharmacol

Inhibition of KPNA2 by ivermectin reduces E2F1 nuclear translocation to attenuate keratinocyte proliferation and ameliorate psoriasis-like lesions. [Abstract]

2024 Oct 9;143(Pt 1):113360. PMID: 39388894
Eur J Pharmacol

The mechanism by which ATP regulates alcoholic steatohepatitis through P2X4 and CD39. [Abstract]

2022 Feb 5:916:174729. PMID: 34973190
Neuropharmacology

Ivermectin reduces withdrawal-induced alcohol intake in rats: Association with CeA GABAergic enhancement and P2rx4 genetic liability. [Abstract]

2026 Feb 12:110881. PMID: 41690511
Mol Oncol

Importin subunit beta-1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. [Abstract]

2025 Jan;19(1):99-113. PMID: 38965815
Cancers (Basel)

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. [Abstract]

2021 Aug 6;13(16):3978. PMID: 34439134
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
J Cell Mol Med

Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential. [Abstract]

2024 Jul;28(14):e18539. PMID: 39046364
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
ACS Pharmacol Transl Sci

Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model. [Abstract]

2024 Jul 17;7(8):2496-2506. PMID: 39144564
Viruses

Importin Alpha Is Implicated in the Nuclear Import of Novel Duck Reovirus Protein p18. [Abstract]

2026 Feb 10;18(2):221. PMID: 41754564
Acta Biochim Biophys Sin (Shanghai)

Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway. [Abstract]

2024 Nov 22;57(6):995-1005. PMID: 39574166
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Virology

Evaluating anti-viral effect of Ivermectin on porcine epidemic diarrhea virus and analyzing the related genes and signaling pathway by RNA-seq in vitro. [Abstract]

2023 Oct:587:109877. PMID: 37688922
J Anim Physiol Anim Nutr (Berl)

Effect of air temperature on growth performance, apparent digestibilities, rumen fermentation and serum metabolites in Altay and Hu lambs. [Abstract]

2020 Jul;104(4):1024-1033. PMID: 32011791
Cancer Chemother Pharmacol

Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells. [Abstract]

2024 Jan;93(1):41-54. PMID: 37741955
Connect Tissue Res

Collagen I alleviates UVB-induced oxidative DNA damage and inhibits YAP-p73 apoptotic pathway in human keratinocytes HaCaT. [Abstract]

2026 May;67(3):243-257. PMID: 41700367
Neurosci Lett

P2X4 receptor in the dorsal horn contributes to BDNF/TrkB and AMPA receptor activation in the pathogenesis of remifentanil-induced postoperative hyperalgesia in rats. [Abstract]

2021 Apr 17:750:135773. PMID: 33639220
Anticancer Res

Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin. [Abstract]

2025 Feb;45(2):451-455. PMID: 39890170
Anticancer Res

Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. [Abstract]

2025 Jan;45(1):97-103. PMID: 39740811
bioRxiv

Ivermectin Reduces Withdrawal-Induced Alcohol Intake via CeA GABAergic Enhancement. [Abstract]

2025 Oct 15:2025.10.14.682432. PMID: 41279989
Patent

US20250235403A1.
bioRxiv

Monolithic Shape-Shifting Absorbable Implants for Long-Term Contraception. [Abstract]

2025 May 23:2025.05.18.654764. PMID: 40475632
bioRxiv

2025 March 19.
bioRxiv

2025 January 14.
Patent

US20240417738A1.
Oxid Med Cell Longev

FOXO1 Is a Critical Switch Molecule for Autophagy and Apoptosis of Sow Endometrial Epithelial Cells Caused by Oxidative Stress. [Abstract]

2021 Dec 21:2021:1172273. PMID: 34970413

溶剤 & 溶解度

体外:

DMSO : 250 mg/mL (285.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1427 mL

5.7137 mL

11.4274 mL

5 mM

0.2285 mL

1.1427 mL

2.2855 mL

10 mM

0.1143 mL

0.5714 mL

1.1427 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

濃度

体積

分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始)

体積 _(開始)

濃度 _(終了)

体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 3.33 mg/mL (3.81 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (288 KB)
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Portuguese - PT (623 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Khakh BS, et al. Allosteric control of gating and kinetics at P2X(4) receptor channels. J Neurosci. 1999 Sep 1;19(17):7289-99. [Content Brief]

[2]. Priel A, et al. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004 Mar;123(3):281-93. [Content Brief]

[3]. Wagstaff KM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012 May 1;443(3):851-6. [Content Brief]

[4]. Raza S, et al. Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication. Microorganisms. 2020 Mar 13;8(3). pii: E409. [Content Brief]

[5]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1427 mL	5.7137 mL	11.4274 mL	28.5685 mL
	5 mM	0.2285 mL	1.1427 mL	2.2855 mL	5.7137 mL
	10 mM	0.1143 mL	0.5714 mL	1.1427 mL	2.8568 mL
	15 mM	0.0762 mL	0.3809 mL	0.7618 mL	1.9046 mL
	20 mM	0.0571 mL	0.2857 mL	0.5714 mL	1.4284 mL
	25 mM	0.0457 mL	0.2285 mL	0.4571 mL	1.1427 mL
	30 mM	0.0381 mL	0.1905 mL	0.3809 mL	0.9523 mL
	40 mM	0.0286 mL	0.1428 mL	0.2857 mL	0.7142 mL
	50 mM	0.0229 mL	0.1143 mL	0.2285 mL	0.5714 mL
	60 mM	0.0190 mL	0.0952 mL	0.1905 mL	0.4761 mL
	80 mM	0.0143 mL	0.0714 mL	0.1428 mL	0.3571 mL
	100 mM	0.0114 mL	0.0571 mL	0.1143 mL	0.2857 mL

Ivermectin

48 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

イベルメクチン

Anti-Infection Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Antiparasitic Compound library

Microbial Metabolite Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

FDA-Approved Anticancer Drug Library

Nuclear Receptor Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Pesticide Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Animal Drug Library

Natural Product Diversity Scaffold Library

Environmental Pollutant Compound Library

RNA Binding Bioactive Compound Library

Bacteria-Sourced Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Ivermectin

HIV アイソフォーム固有の製品をすべて表示

Antibiotic アイソフォーム固有の製品をすべて表示

Parasite アイソフォーム固有の製品をすべて表示

HSV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (48)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Ivermectin 関連分類

製品番号: HY-15310